Next-Gen Breast Cancer Drugs Offer Patients Hope

Editor's Note: In the video below, Michael Douglass indicates that only a subset of patients in the phase 1 trial for bemaciclib had breast cancer. All of the patients in the phase 1 trial had breast cancer, but subsets had different types of breast cancer. The Motley Fool and the analyst regret the error.

The American Association for Cancer Research's meeting last weekend yielded some big news from Pfizer's (NYSE: PFE  ) and Amgen's (NASDAQ: AMGN  ) palbociclib and Eli Lilly's (NYSE: LLY  ) bemaciclib. These drugs, which are part of the new CDK 4/6 inhibitor class, have generated a lot of excitement, particularly given the recent data releases.

Palbociclib generated a statistically significant, 10-month increase in progression-free survival (PFS) in a phase 2 trial, while bemaciclib reported about a 9 month median increase in PFS for hormone receptor positive breast cancer patients in its phase 1 trial.

Some analysts have speculated that Pfizer might seek an early submission to the FDA based on the palbociclib trial data so far, and investors are going to want to watch these companies and drugs very closely for the next release of data.

In this video from Tuesday's Market Checkup, Motley Fool health care analysts David Williamson and Michael Douglass discuss the recent drug data and what that means for investors moving forward.

3 stocks poised to be multi-baggers
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multi-bagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2909284, ~/Articles/ArticleHandler.aspx, 10/31/2014 4:14:20 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement